Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03589950 |
Recruitment Status : Unknown
Verified July 2018 by The First People's Hospital of Lianyungang.
Recruitment status was: Not yet recruiting
First Posted : July 18, 2018
Last Update Posted : July 18, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Lung Neoplasms Docetaxel Pemetrexed S-1 Anlotinib | Drug: anlotinib plus chemotherapy Drug: chemotherapy | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Parallel Control, Exploratory Trial to Compare Anlotinib Plus Chemotherapy Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Non-small Cell Lung Cancer |
Estimated Study Start Date : | August 1, 2018 |
Estimated Primary Completion Date : | August 1, 2020 |
Estimated Study Completion Date : | August 1, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Anlotinib plus chemotherapy
Anlotinib (12mg QD PO d1-14, 21 days per cycle) + Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
|
Drug: anlotinib plus chemotherapy
Anlotinib (12mg QD PO d1-14, 21 days per cycle), Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle) |
Active Comparator: Chemotherapy
Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle)
|
Drug: chemotherapy
Docetaxel (75mg/m2 IV d1)/Pemetrexed (500 mg/m2 IV d1), q21d/S-1 (80-120mg/day,depending on body surface area; days 1-28 in a 6-week cycle) |
- PFS [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months ]progression-free survival
- DCR [ Time Frame: Time Frame: each 42 days up to intolerance the toxicity or PD (up to 24 months) ]Disease Control Rate
- OS [ Time Frame: From randomization until death (up to 24 months) ]Overall survival
- ORR [ Time Frame: each 21 days up to the toxicity or PD (up to 24 months) ]Objective Response Rate
- Quality of life score [ Time Frame: each 21 days up to the toxicity or PD (up to 24 months) ]Quality of life score
- Safety [ Time Frame: each 21 days up to the toxicity or PD (up to 24 months) ]Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age:18~75 years;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 -2
- Subjects with histologically or cytologically confirmed locally advanced or advanced NSCLC who have previously received one lines chemotherapy, EGFR TKI or ALK inhibitor (whom with EGFR or ALK mutation but not with T790 M positive) treatment before participating;
- Subjects with at least one measurable lesion as defined by RECIST (version 1.1),which is confirmed by computed tomography (CT) scan or MRI .
- Subjects without brain metastases or asymptomatic brain metastases, and not needing for dehydrating agents or corticosteroids to control intracranial symptoms;
- Survival expectation ≥ 3 months;
- The main organ function is normal;
- Females of childbearing potential must be a pregnancy test in 7 days before participating ( including serum or urine), and the results were negative.
- Subjects provided written informed consent before participating, willing and able to comply with all aspects of the protocol
Exclusion Criteria:
1. Small Cell Lung Cancer; 2. Subjects with symptomatic brain metastases; 3. Survival expectation < 3 months; 4. examined as positive in EGFR&ALK mutation detection and never take the treatment of TKIs 5. Blood transfusion is required in the first dose of drug treatment within 14 days ; 6. The interval of subjects had received chemotherapy, biotherapy, radiotherapy or other anticancer therapies in the first dose of drug treatment within 21 days(excluding palliative radiotherapy); 7. The risk of active bleeding; 8. Subjects with uncontrolled blood pressure with medication (140/90 mmHg) 9. Laboratory values and organ functions : (1)Hematologic insufficiency:
- Hemoglobin (Hb)<8.5 g/dL,
- Absolute neutrophil count (ANC)≤1.5×109/L,
- Platelet count (PLT)< 100×109/L; (2)Insufficient liver function:
- Bilirubin > 1.5×the upper limit of normal (ULN)
- Alanine aminotransferase (ALT), or Aspartate aminotransferase (AST) >3.0×(ULN), When liver metastases,Bilirubin > 1.5×ULN, ALT or AST >5.0×(ULN.
- serum creatinine ≤1.0×(ULN), or creatinine clearance > 50 mL/min( calculated per the Cockcroft and Gault formula) (3) Subjects with positive for HBV surface antigen ( HBsAg)or anti-hcv (4)Subjects with Interstitial lung disease (5)Insufficient renal function: serum creatinine≥ 1.5×(ULN), or creatinine clearance <60 mL/min
10. impairment of heart function: (1)Left ventricular ejection fraction (LVEF) <45% (LVEF evaluation is not required for subjects have no history of congestive heart failure), (2)Unstable angina, (3)Severe arrhythmia, (4)NYHA III or IVgrade of congestive heart failure, (5) Subjects with myocardial infarction within the last 12 months before entering the trial, (6)Pericardial effusion, 11. Subjects with liver fibrosis or hepatic cirrhosis 12. (1)Subjects with other active malignancy (except for definitively treated non melanoma skin cancer,carcinoma in-situ of the cervix,or other cancers that are treated with curative treatment and have no signs of recurrence for at least 5 years ) , (2)Subjects with dysphagia,malabsorption,chronic gastrointestinal diseases,or other medical history may hinder compliance and / or experimental drug absorption, 13. Subjects with major surgery in the first dose of drug treatment within 28 days, 14. Subjects with positive unknown human immunodeficiency virus.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03589950
Contact: xiaodong jiang, MD | 18961326201 | jxdysy1970@163.com |
China, Jiangsu | |
The Affiliated Lianyungang Hospital of Xuzhou Medical University | |
Lianyungang, Jiangsu, China, 222002 | |
Contact: xiaodong jiang, MD 18961326201 jxdysy1970@163.com | |
Sub-Investigator: lijun liang, MM | |
Sub-Investigator: yixuan wen, MM |
Responsible Party: | The First People's Hospital of Lianyungang |
ClinicalTrials.gov Identifier: | NCT03589950 |
Other Study ID Numbers: |
Anlo01 |
First Posted: | July 18, 2018 Key Record Dates |
Last Update Posted: | July 18, 2018 |
Last Verified: | July 2018 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
anlotinib docetaxel pemetrexed |
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases |